Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in... (al trials (n860) adverse reactions thato...)

Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World

Date:8/19/2007

al trials (n=860), adverse reactions that occurred at a rate greater than or equal to two percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than two percent. ENDOMETRIN is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness).

About BRAVELLE and MENOPUR

BRAVELLE (urofollitropin for injection, purified) and MENOPUR (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Like other products for ovarian stimulation, treatment with BRAVELLE and/or MENOPUR may result in multiple gestations. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE, MENOPUR, REPRONEX(R) (menotropins for injection, USP), NOVAREL and ENDOMETRIN in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and
'/>"/>

SOURCE Georgia Reproductive Specialists

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
2. Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting
3. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
8. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
9. ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
10. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
11. Genetic Analysis Systems Enter the Clinical Mainstream

Post Your Comments:

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

(Date:5/21/2013)... CEO of Mammotome, a division of Devicor Medical Products, has ... Cincinnati chapter of the Association for Corporate Growth ... who is also a breast cancer survivor, led the purchase ... 2010. Daulton will be presented with the award at the ... May 22. The ACG Deal Maker Awards program ...

(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... ZURICH, July 16 An innovative treatment ... patients has received a second,orphan drug designation in ... was,granted. The recent designation relates to Burkholderia cepacia ... patients. For Axentis,Pharma AG of Zurich, Switzerland, both ...

... , BOSTON and EDISON, N.J., July ... with edoxaban(2) - an investigational oral Factor Xa inhibitor - ... receiving edoxaban once daily (QD) experienced fewer bleeding events than ... that bleeding associated with edoxaban is most closely correlated with ...

Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2 Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

(Date:5/21/2013)... May 21, 2013 ContinuCare Home Health, ... Department of Aging and Disability Services. After completing a ... interviews, ContinuCare Home Health was found to have ... is part of the Department of Aging and Disability ... and disability services, supports and opportunities that are ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Artisan ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, ... will focus on exploring alternative finance through EB-5 ... latest market, legal and economic information, and updates ... legal professionals within the EB-5 industry. , ...

(Date:5/21/2013)... May 21, 2013 According to a May ... the Use of Botox,” Botox injections have become ... approval in 2002 (Go to goo.gl/8iYbD). Although it is mostly ... with men. The injection makes facial wrinkles less visible by ... last for about three months. This means that people who ...

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...

(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...

Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis

... Boston Scientific,Corporation (NYSE: BSX ) today announced ... ALTRUA(TM) family of pacemakers. ALTRUA is Boston,Scientific,s most ... small size and battery longevity. It is the ... in which the,heart beats too slowly -- usually ...

... Inc.,("GNC" or the "Company"), the largest global specialty ... for the first,quarter ended March 31, 2008., ... of GNC Parent LLC,which was acquired on March ... and Ontario Teachers, Pension Plan Board ("Teachers"). As ...

... Alimera Sciences Inc., a privately held,ophthalmic pharmaceutical ... pilot study to assess the safety and efficacy ... Genentech) in patients,with exudative age-related macular degeneration (wet ... performed under an investigator,sponsored IND, will compare two ...

... Market Share in Europe and Canada; ... LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. ... first quarter ended March,31, 2008. All figures are in ... to make strong progress in the global,commercialization of our ...

... Appeals for More than $8 million for medicines and other lifesaving ... ... As the death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely ... sanitary conditions,could significantly increase the death toll among children and other,vulnerable populations, ...

... Inc. ("Holdings",or the "Company"), the parent company of ... largest cancer services companies, reported revenue of,$810.6 million, ... flow of,$50.9 million for the quarter ended March ... those of US Oncology, its wholly-owned,subsidiary, through which ...

Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)Labopharm Reports Results for First Quarter Fiscal 2008 Myanmar Cyclone a Children's Catastrophe - UNICEF US Oncology Reports First Quarter 2008 Results

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Pelvic Washing for Cytology PBG, Urine Quantitative Parvovirus B19 Antibody, IgM Parvovirus B 19, by PCR, Bone Marrow